An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain
Sponsor: Boehringer Ingelheim
This PHASE4 trial investigates Diabetic Neuropathy, Painful and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .